Dare Bioscience, Inc.

Dare Bioscience, Inc. announced a strategic collaboration with MyMenopauseRx, a specialized telehealth platform focused on menopause care. This partnership will feature MyMenopauseRx as a menopause-specific telehealth partner for DARE to PLAY™ Sildenafil Cream, providing women with access to menopause specialists alongside arousal support. The collaboration is a key step in Daré’s strategy to build a comprehensive women’s health ecosystem, enhancing commercial reach and consumer engagement.

Dare Bioscience, Inc. announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative. Hosted by CEO Sabrina Martucci Johnson, the series will offer shareholders direct access to leadership to discuss the company's commercial strategy, women's health portfolio, growth opportunities, and long-term vision. The events will also provide details on Daré's ongoing Regulation A offering, with four sessions scheduled from July 23 to August 26, 2026.

Dare Bioscience, Inc. received a notice from Nasdaq on July 13, 2026, indicating non-compliance with Listing Rule 5550(b). This is due to the company's stockholders' equity being less than $2.5 million and not meeting alternative requirements of $35 million in market value or $500,000 in net income. The company's common stock is subject to delisting unless it timely requests a hearing. Dare Bioscience plans to request a hearing, which will temporarily stay the delisting process, but there is no guarantee of an extension or regaining compliance.

Dare Bioscience, Inc. announced its participation in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET. President and CEO Sabrina Martucci Johnson will provide a corporate overview, highlighting the recent launch of FloraSync LF5™, the company's commercial strategy, pipeline advancements, and milestones for long-term growth. The event will also cover Dare's approach to capital allocation and include a live Q&A session.

Dare Bioscience, Inc. announced the commercial availability of Flora Sync LF5, a vaginal probiotic capsule, marking the company's first direct consumer product revenue. This launch signifies Dare Bioscience's transition to a women's health company with a revenue-generating product. The company also provided updates on its pipeline, including the upcoming dispensing of DARE to PLAY Sildenafil Cream, the initiation of a Phase 2 study for DARE-HPV, and positive interim results for its Ovaprene Phase 3 study.

Dare Bioscience announced its participation in a Virtual Investor segment highlighting the upcoming June 2026 commercial launch of Flora Sync LF5™. This vaginal probiotic capsule is the company's first consumer health product, positioning Dare for direct revenue generation. The launch is a significant step in expanding its women's health leadership platform and diversifying its portfolio while advancing clinical-stage programs.

Dare Bioscience, Inc. has filed an 8-K furnishing a corporate presentation dated June 22, 2026. The company intends to use this presentation in various meetings with securities market participants and will make it available in the 'Investors' section of its website.

Daré Bioscience announced that its President and CEO, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a corporate presentation at the BIO International Convention 2026, taking place from June 22-25 in San Diego. The company aims to highlight its progress and differentiated portfolio in women's health, engaging with global industry leaders, investors, and potential collaborators. This participation underscores Daré's growing leadership role in advancing innovation and accelerating solutions for women's healthcare.

Dare Bioscience, Inc. held its 2026 annual meeting of stockholders, where several key proposals were approved. Stockholders voted to amend the 2022 Stock Incentive Plan, increasing the number of shares available for issuance by 1,500,000. Additionally, directors were elected, the independent auditor was ratified, and the potential future issuance of shares under an existing equity line was approved. The board also determined to hold an advisory vote on executive compensation annually.

Dare Bioscience announced the upcoming commercial launch of Flora Sync LF5, a vaginal probiotic capsule, marking its transition to a revenue-generating company with first direct consumer product revenue expected in June 2026. The product will be marketed under the DARE to RESTORE brand and manufactured by Probiotical S.p.A. The company also provided updates on its pipeline, including the initiation of a Phase 2 study for DARE-HPV, positive interim results for Ovaprene, and the targeted summer launch of DARE to PLAY Sildenafil Cream.